Researchers discuss generic drug market failure, whereby a generic drug manufacturer increases the drug price, which can compromise care.
Making Alternative Payment Plans Mandatory: Inherent Risks and Pitfalls in Reducing Healthcare CostsMay 15, 2018
The Center for Medicare and Medicaid Innovation (CMMI) program was created by the Affordable Care Act to identify and test new strategies for reimbursement in an effort to reduce growing healthcare costs.
Patients who use medical marijuana may be more likely to use prescription drugs for both medical and nonmedical purposes.
FDA Commissioner, Scott Gottlieb MD, said, "The FDA shares the goal of ensuring that American patients have access to quality and affordable care that meets their needs."
Regulatory requirements are likely to be an important aspect of physician dissatisfaction with electronic health records that is driving burnout.
Only 19 percent of organizations use computer software to monitor compliance with Final Rule.
The approval was based on a 12-week, double-blind, placebo-controlled study (N=295) in pediatric patients 4-17 years of age.
The Department of Health and Human Services has announced the creation of the Conscience and Religious Freedom Division within the HHS Office of Civil Rights.
Survey finds that 98 percent of respondents report experiencing drug shortages on a consistent basis.
U.S. hospitals will have to post their standard prices online and make it easier for patients to access their electronic medical records, Medicare officials said.
Researchers examined the scale and growth trajectory of the online marketplace for marijuana by analyzing aggregate internet searches and the links searchers typically found.
The position paper focuses on the 4 accepted principles of healthcare: beneficence, nonmaleficence, justice, and respect for autonomy.
A recent paper examines the circumstances in which public good outweighs the requirement that researchers receive individual consent to use a person's data.
The FDA said it wants all companies making kratom products to take them off the market, and urged all consumers who have kratom-containing products to stop using them and throw them away.
Although the Affordable Care Act's coverage expansions have reduced out-of-pocket spending for low- and middle-income individuals, these patients continue to experience a high burden of premium and out-of-pocket spending.
Federal "right-to-try" legislation will restrict the FDA's oversight of access to investigational drugs for patients with life-threatening illnesses and diminish the FDA's public health mission
Many healthcare organizations are calling on Congress to reverse the new Centers for Medicare & Medicaid Services policy that has the potential to jeopardize patient access to Part B drug therapies.
Experts advise that should the CDC be banned from using certain words, it could give rise to at least 7 harmful consequences.
The FDA has accepted a New Drug Application for an investigational topical twice-a-day product for the treatment of inflammation and pain in patients who have undergone ocular surgery.
Aetna will have access to data on pharmaceutical usage patterns that will give the company the opportunity to figure out who is willing to pay more for healthcare. What does this mean for patients?
Policy analysts at the Centers for Disease Control and Prevention have been informed to stop using certain terms in documents to be used in next year's budget.
Scientists warn that unless there is an adequate response and proactive measures are taken, society will soon have to deal with direct and indirect effects of the changing climate on human health.
After the Republicans passed their tax reform bill in the Senate over the weekend, the American Heart Association released a statement detailing their concerns about the legislation.
The Food and Drug Administration's Commissioner Scott Gottlieb, MD, has issued a statement regarding the deadly risks associated with the botanical substance, kratom.
Medicaid's best-price rule is not as serious a problem as drug manufacturers imply, although it may affect novel pricing arrangements.
Here are five potentially pivotal MACRA issues that you should know about.
Enhancing health equity and addressing societal healthcare disparities is dependent on American medical schools committing to a social mission.
Market competition levels are associated with changes in the price of generic drugs.
Researchers are urging legislators to assign ICD codes to all medical devices, which could help identify device-related adverse effects more accurately.
Researchers found that marijuana use increases risk of hypertension-related death by three-fold, and marijuana use is linked to greater cardiovascular risks than cigarette smoking.
Clinical Pain Advisor Articles
- Opioid Use in Chronic Low Back Pain: A Population Study
- Risks Associated With Co-Administration of Aspirin and Other NSAIDs
- Stages of Low Back Pain Have Specific Sets of Clinical Indicators
- FDA Approves Aimovig for Migraine Prevention
- First Non-Opioid Drug Approved for Managing Opioid Withdrawal Symptoms
- Effect of Prescription Drug Monitoring Programs on Fatal, Nonfatal Drug Overdoses
- Standardized SCS Workflow May Effectively Alleviate Failed Back Surgery Syndrome-Related Pain
- Marijuana Legalization and Opioid Prescribing Rates
- Medical Marijuana Users More Likely to Use Prescription Drugs for Medical, Nonmedical Purposes
- Interbrain Coupling During Handholding Associated With Analgesia, Empathy
- Opioid-Related Adverse Drug Events Associated With Worse Patient, Cost Outcomes
- Education Plus Exercise, Single Corticosteroid Injection Effective in Long Term for Gluteal Tendinopathy
- Detox vs Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Expert Roundtable
- Naloxone Training Beneficial for PA Students
- Supervised Injection Sites Hailed as the Latest Strategy to Fight the Opioid Crisis